THM Capital Advisory raises funds for Cutting Edge

THM Capital Advisory supports Cutting Edge in its fundraising to accelerate the development of its range of hydrophobic intraocular implants.

Cutting Edge announces a fund raising from a chemical group specialized in the production of polymers, its two founding directors Yves Brouquet and Jean-Pierre Boudet, as well as a private shareholder. THM Capital Advisory acted as financial advisor to the managers in connection with this transaction.

Founded in 2015 and based in Labège (31), Cutting Edge designs, produces and markets intraocular implants for the treatment of cataracts. The company has developed a complete range and obtained 9 CE markings, testifying to the maturity of its product portfolio.

Historically specialized in hydrophilic polymer implants, Cutting Edge is taking a new step forward by strengthening its equity to increase its production capacity for hydrophobic polymer implants, for which global demand is growing rapidly.

This fundraising should enable the company to accelerate its commercial development in France and abroad in around twenty countries, before continuing to extend its product range — through internal R&D developments or by acquisition — from 2023.

THM Capital Advisory advised the managers as financial advisor (Thomas Mitard), alongside Eleom Avocats (Pascal Roze) as legal advisor.

The investor was accompanied by Themis Conseils (Cindy Mantovani-Lefèvre) for the legal aspect.